Axsome Therapeutics (AXSM) Cash from Financing Activities (2015 - 2026)

Axsome Therapeutics has disclosed Cash from Financing Activities across 12 years of filings, most recently posting $3.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $3.0 million, down 89.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.2 million (down 14.85% YoY), and the FY2025 annual result was $101.5 million, up 75.42% from the prior year.
• Cash from Financing Activities came in at $3.0 million for Q1 2026 at Axsome Therapeutics, down from $16.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $246.1 million in Q2 2023 to a low of -$1.2 million in Q1 2024.
• The 5-year median for Cash from Financing Activities is $29.3 million (2025), against an average of $45.8 million.
• Peak annual rise in Cash from Financing Activities reached 712300.0% in 2024, while the deepest fall reached 102.3% in 2024.
• Axsome Therapeutics' Cash from Financing Activities stood at $1.1 million in 2022, then plunged by 100.19% to -$2000.0 in 2023, then surged by 712300.0% to $14.2 million in 2024, then advanced by 15.03% to $16.4 million in 2025, then slumped by 81.73% to $3.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.0 million (Q1 2026), $16.4 million (Q4 2025), and $21.3 million (Q3 2025), per Business Quant data.